Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

JULÄINE™ - Neck Skin Laxity Clinical Investigation

10 de noviembre de 2026 actualizado por: Nordberg Medical AB

A Prospective, Multi-Centre, Single-Arm, Open-Label Pivotal Clinical Investigation to Evaluate the Safety and Clinical Performance of JULÄINE™ in Adults With Neck Skin Laxity

This study will assess the safety of JULÄINE™, an injectable filler containing poly-L-lactic acid (PLLA), and whether it can improve loose skin on the neck.

The main question is whether more than 60% of treated participants show an improvement of at least one level on a neck skin laxity scale, 26 weeks after their final treatment. Improvement will be measured by comparing neck skin looseness before and after treatment.

The study plans to enroll adults aged 18 years or older with mild to moderately severe loose neck skin at three sites. All participants will receive the filler during three treatment sessions, approximately four weeks apart.

Participation will last approximately 14 months, including screening, treatment, and follow-up until 52 weeks after the final treatment. Investigators will assess changes using standardised photographs, measurements of skin elasticity, and questionnaires about participants' views of their neck appearance. The study will also monitor adverse events through the final follow-up visit.

Descripción general del estudio

Estado

Aún no reclutando

Condiciones

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Estimado)

68

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Adults aged 18 years or older with mild to moderate-to-severe neck skin laxity (Grade 2-4 on Neck Laxity Scale).
  • Willing to avoid aesthetic procedures involving the neck and lower face and changes to treatments affecting skin quality during the study.
  • If of childbearing potential, a negative pregnancy test and agreement to use highly effective contraception throughout treatment and for eight weeks afterward.
  • Able to provide written informed consent and comply with study visits, assessments, and post-treatment instructions.

Exclusion Criteria:

  • Pregnancy, breastfeeding, or planned pregnancy or reproductive donation/retrieval procedures during the study or within eight weeks after the final visit.
  • Previous neck surgery or major maxillofacial/cervical surgery; neck injections within 12 months; neck resurfacing or other aesthetic procedures within six months; or planned procedures during the study.
  • Significant neck skin disease, infection, scarring, pigmentation abnormalities, or other conditions interfering with treatment or assessment.
  • Prominent neck muscle bands, excessive facial or neck fat, or anatomy unsuitable for injectable treatment, as assessed by the investigator.
  • Significant thyroid enlargement, uncontrolled thyroid disease, or other unstable endocrine disease.
  • Allergy to device components, coagulation disorders, or anticoagulant/antiplatelet treatment, subject to protocol-defined exceptions.
  • Recent immune-modifying treatment, chemotherapy, or systemic corticosteroids above 10 mg prednisone-equivalent daily; relevant corticosteroid/retinoid use; or treatments affecting collagen production.
  • Hormone replacement therapy or thyroid medication that does not meet protocol-defined stability requirements.
  • Immune deficiency, autoimmune disease, impaired wound healing, or significant malignant, dermatological, or systemic disease.
  • Significant recent or expected weight changes, recent bariatric surgery, ongoing postoperative weight loss, or active weight-loss treatment, subject to protocol-defined exceptions.
  • Any condition preventing valid informed consent or compliance with study requirements.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: JULÄINE™

JULÄINE™, a poly-L-lactic acid (PLLA)-based injectable filler, administered beneath the skin on both sides of the neck during three treatment sessions, approximately four weeks apart.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Percentage of Participants With Improved Neck Skin Laxity
Periodo de tiempo: Baseline and 26 weeks after the final treatment session

Percentage of participants showing an improvement of at least one grade from baseline on Neck Laxity Scale. The scale ranges from Grade 1 to Grade 5. A decrease in grade indicates improvement.

Baseline and 26 weeks after the final treatment session

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Percentage of Participants With Improved Neck Skin Laxity at 12 and 52 Weeks
Periodo de tiempo: Baseline and 12 and 52 weeks after the final treatment session

Percentage of participants showing an improvement of at least one grade from baseline on Neck Laxity Scale. The scale ranges from Grade 1 to Grade 5. A decrease in grade indicates improvement.

Baseline and 12 and 52 weeks after the final treatment session
Percentage of Participants With Improved Neck Skin Elasticity
Periodo de tiempo: Baseline and 26 weeks after the final treatment session

Percentage of participants showing an increase of at least 10% from baseline in the Cutometer R2 parameter, a measure of overall skin elasticity. Higher R2 values indicate greater elasticity.

Baseline and 26 weeks after the final treatment session
Investigator-Rated Change in Neck Appearance
Periodo de tiempo: 12, 26, and 52 weeks after the final treatment session

Distribution of investigator ratings on the seven-point Global Aesthetic Improvement Scale, ranging from "very much improved" to "very much worse," based on comparisons of standardised post-treatment and baseline photographs.

12, 26, and 52 weeks after the final treatment session
Change From Baseline in FACE-Q Appraisal of the Neck Score
Periodo de tiempo: Baseline and 12, 26, and 52 weeks after the final treatment session.

Change from baseline in participants' assessment of their neck appearance using the FACE-Q Appraisal of the Neck questionnaire. Raw scores are converted to a score ranging from 0 to 100 using the instrument's scoring algorithm.

Baseline and 12, 26, and 52 weeks after the final treatment session.
Change From Baseline in Neck Skin Firmness and Elasticity Measured by Cutometer
Periodo de tiempo: Baseline and 12, 26, and 52 weeks after the final treatment session.

Change from baseline in four Cutometer parameters: R0 (skin firmness), R2 (gross elasticity), R5 (net elasticity), and R7 (biological elasticity). Lower R0 values indicate firmer skin, while higher R2, R5, and R7 values indicate greater elasticity.

Baseline and 12, 26, and 52 weeks after the final treatment session.
Incidence of Adverse Events and Device Deficiencies
Periodo de tiempo: From the first treatment through 52 weeks after the final treatment session

Number and percentage of participants experiencing adverse events, including device-related events, serious events, and unanticipated serious device-related events. Events will be characterised by type, severity, seriousness, and relationship to the device or injection procedure. Device deficiencies will be summarised separately.

From the first treatment through 52 weeks after the final treatment session

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de julio de 2027

Finalización primaria (Estimado)

1 de agosto de 2028

Finalización del estudio (Estimado)

1 de enero de 2029

Fechas de registro del estudio

Enviado por primera vez

10 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

10 de noviembre de 2026

Publicado por primera vez (Actual)

16 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

16 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

10 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • NB 15-TF-EU-100-38F

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .